Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs

Frontiers in Behavioral Neuroscience

Volumn 8, Issue MAY, 2014, Pages

  Tannenbaum, Pamela L ^a   Stevens, Joanne ^a   Binns, Jacquelyn ^a   Savitz, Alan T ^a   Garson, Susan L ^a   Fox, Steven V ^a   Coleman, Paul ^a   Kuduk, Scott D ^a   Gotter, Anthony L ^a   Marino, Michael ^a   Tye, Spencer J ^a   Uslaner, Jason M ^a   Winrow, Christopher J ^a   Renger, John J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arousal; Auditory discrimination; DORA; Hypocretin; Orexin; Sleep

Indexed keywords

DIAZEPAM; DIPHENHYDRAMINE; DUAL OREXIN RECEPTOR ANTAGONIST; ESZOPICLONE; OREXIN; OREXIN RECEPTOR; PLACEBO; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; AROUSAL; ARTICLE; AUDITORY STIMULATION; CATAPLEXY; CONTROLLED STUDY; DRUG TARGETING; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; ELECTROOCULOGRAM; EXPERIMENTAL DOG; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REWARD; SEDATION; SLEEP TIME; SLEEP WAKING CYCLE; STIMULUS RESPONSE; TELEMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84901364149     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2014.00182     Document Type: Article

References (46)

1. Babcock, D. A., Narver, E. L., Dement, W. C., and Mitler, M. M. (1976). Effects of imipramine, chlorimipramine and fluoxetine on cataplexy in dogs. Pharmacol. Biochem. Behav. 5, 599-602. doi: 10.1016/0091-3057(76)90298-7
2. Barnett, A., Iorio, L. C., Kreutner, W., Tozzi, S., Ahn, H. S., and Gulbenkian, A. (1984). Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. Agents Actions 14, 590-597. doi: 10.1007/BF01978891
3. Bertini, S., Buronfosse, F., Pineau, X., Berny, P., and Lorgue, G. (1995). Benzodiazepine poisoning in companion animals. Vet. Hum. Toxicol. 37, 559-562.
4. Bettica, P., Nucci, G., Pyke, C., Squassante, L., Zamuner, S., Ratti, E., et al. (2012a). Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J. Psychopharmacol. 26, 1058-1070. doi: 10.1177/0269881111408954
5. Bettica, P., Squassante, L., Groeger, J. A., Gennery, B., Winsky-Sommerer, R., and Dijk, D. J. (2012b). Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM Sleep and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37, 1224-1233. doi: 10.1038/npp.2011.310
6. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155. doi: 10.1038/nm0507-525
7. Buendia, N., Goode, M., Sierra, G., and Segundo, J. P. (1963). Responsiveness and discrimination during sleep. Experientia 19, 208-209. doi: 10.1007/bf02172319
8. Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451. doi: 10.1016/s0092-8674(00)81973-x
9. Coenen, A. (2010). Subconscious stimulus recognition and processing during sleep. Psyche 16, 90-97.
10. Coleman, P. J., Schreier, J. D., Cox, C. D., Breslin, M. J., Whitman, D. B., Bogusky, M. J., et al. (2012). Discovery of [(2R,5R)-5-[(5-fluoropyridin-2-yl)oxy]methyl-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem. 7, 415-424 337. doi: 10.1002/cmdc.201200025
11. Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., et al. (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320-5332. doi: 10.1021/jm100541c
12. Dillon, R. F., and Webb, W. B. (1965). Threshold of arousal from "activated" sleep in the rat. J. Comp. Physiol. Psychol. 59, 446-447. doi: 10.1037/h0022038
13. Fox, S. V., Gotter, A. L., Tye, S. J., Garson, S. L., Savitz, A. T., Uslaner, J. M., et al. (2013). Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 38, 2401-2408. doi: 10.1038/npp.2013.139
14. Giorgi, M., Portela, D. A., Breghi, G., and Briganti, A. (2012). Pharmacokinetics and pharmacodynamics of zolpidem after oral administration of a single dose in dogs. Am. J. Vet. Res. 73, 1650-1656. doi: 10.2460/ajvr.73.10.1650
15. Gotter, A. L., Webber, A. L., Coleman, P. J., Renger, J. J., and Winrow, C. J. (2012). International union of basic and clinical pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol. Rev. 64, 389-420. doi: 10.1124/pr.111.005546
16. Halperin, J. M., and Iorio, L. C. (1981). Responsitivity of rats to neutral and danger-signaling stimuli during sleep. Behav. Neural Biol. 33, 213-219. doi: 10.1016/s0163-1047(81)91651-4
17. Haynes, A. C., Jackson, B., Chapman, H., Tadayyon, M., Johns, A., Porter, R. A., et al. (2000). A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul. Pept. 96, 45-51. doi: 10.1016/s0167-0115(00)00199-3
18. Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., et al. (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79, 2265-2274. doi: 10.1212/wnl.0b013e31827688ee
19. Herron, M. E., Shofer, F. S., and Reisner, I. R. (2008). Retrospective evaluation of the effects of diazepam in dogs with anxiety-related behavior problems. J. Am. Vet. Med. Assoc. 233, 1420-1424. doi: 10.2460/javma.233.9.1420
20. Johnson, L. C., Spinweber, C. L., Webb, S. C., and Muzet, A. G. (1987). Dose level effects of triazolam on sleep and response to a smoke detector alarm. Psychopharmacology (Berl) 91, 397-402. doi: 10.1007/bf00216003
21. Kushida, C. A., Baker, T. L., and Dement, W. C. (1985). Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr. Clin. Neurophysiol. 61, 61-70. doi: 10.1016/0013-4694(85)91073-9
22. Lancaster, A. R., Lee, J. A., Hovda, L. R., Hardy, B. T., Miyahara, L. X., and Martin, E. P. (2011). Sleep aid toxicosis in dogs: 317 cases (2004-2010). J. Vet. Emerg. Crit. Care (San Antonio) 21, 658-665. doi: 10.1111/j.1476-4431.2011.00694.x
23. Langford, G. W., Meddis, R., and Pearson, A. J. (1974). Awakening latency from sleep for meaningful and non-meaningful stimuli. Psychophysiology 11, 1-5. doi: 10.1111/j.1469-8986.1974.tb00815.x
24. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X. Y., et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376. doi: 10.1016/s0092-8674(00)81965-0
25. Mang, G. M., Durst, T., Burki, H., Imobersteg, S., Abramowski, D., Schuepbach, E., et al. (2012). The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35, 1625-1635. doi: 10.5665/sleep.2232
26. Mendelson, W. B., Martin, J. V., Stephens, H., Giesen, H., and James, S. P. (1988). Effects of flurazepam on sleep, arousal threshold and the perception of being asleep. Psychopharmacology (Berl) 95, 258-262. doi: 10.1007/bf00174520
27. Nishino, S. (2007). Clinical and neurobiological aspects of narcolepsy. Sleep Med. 8, 373-399. doi: 10.1016/j.sleep.2007.03.008
28. Nishino, S., Arrigoni, J., Shelton, J., Kanbayashi, T., Dement, W. C., and Mignot, E. (1997). Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J. Neurosci. 17, 6401-6408.
29. Nordby, H., Hugdahl, K., Stickgold, R., Bronnick, K. S., and Hobson, J. A. (1996). Event-related potentials (ERPs) to deviant auditory stimuli during sleep and waking. Neuroreport 7, 1082-1086. doi: 10.1097/00001756-199604100-00026
30. Nutt, D. J., and Stahl, S. M. (2010). Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J. Psychopharmacol. 24, 1601-1612. doi: 10.1177/0269881109106927
31. Oswald, I., Taylor, A. M., and Treisman, M. (1960). Discriminative responses to stimulation during human sleep. Brain 83, 440-453. doi: 10.1093/brain/83.3.440
32. Perrin, F., Garcia-Larrea, L., Mauguiere, F., and Bastuji, H. (1999). A differential brain response to the subject's own name persists during sleep. Clin. Neurophysiol. 110, 2153-2164. doi: 10.1016/s1388-2457(99)00177-7
33. Portas, C. M., Krakow, K., Allen, P., Josephs, O., Armony, J. L., and Frith, C. D. (2000). Auditory processing across the sleep-wake cycle: simultaneous EEG and fMRI monitoring in humans. Neuron 28, 991-999. doi: 10.1016/S0896-6273(00)00169-0
34. Richardson, J. A., Gwaltney-Brant, S. M., Albretsen, J. C., Khan, S. A., and Porter, J. A. (2002). Clinical syndrome associated with zolpidem ingestion in dogs: 33 cases (January 1998-July 2000). J. Vet. Intern. Med. 16, 208-210. doi: 10.1111/j.1939-1676.2002.tb02357.x
35. Rodgers, R. J., Halford, J. C., Nunes de Souza, R. L., Canto de Souza, A. L., Piper, D. C., Arch, J. R., et al. (2000). Dose-response effects of orexin-A on food intake and the behavioural satiety sequence in rats. Regul. Pept. 96, 71-84. doi: 10.1016/s0167-0115(00)00203-2
36. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585. doi: 10.1016/s0092-8674(00)80949-6
37. Saper, C. B., Scammell, T. E., and Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature 437, 1257-1263. doi: 10.1038/nature04284
38. Siegel, J., and Langley, T. D. (1965). Arousal threshold in the cat as a function of sleep phase and stimulus significance. Experientia 21, 740-741. doi: 10.1007/bf02138511
39. Snyder, F. (1966). Toward an evolutionary theory of dreaming. Am. J. Psychiatry 123, 121-142.
40. Tan, K. R., Rudolph, U., and Luscher, C. (2011). Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 34, 188-197. doi: 10.1016/j.tins.2011.01.004
41. Tsujino, N., and Sakurai, T. (2013). Role of orexin in modulating arousal, feeding and motivation. Front. Behav. Neurosci. 7:28. doi: 10.3389/fnbeh.2013.00028
42. Van Twyver, H., and Garrett, W. (1972). Arousal threshold in the rat determined by "meaningful" stimuli. Behav. Biol. 7, 205-215. doi: 10.1016/s0091-6773(72)80200-1
43. Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., et al. (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J. Neurogenet. 25, 52-61. doi: 10.3109/01677063.2011.566953
44. Winrow, C. J., Gotter, A. L., Cox, C. D., Tannenbaum, P. L., Garson, S. L., Doran, S. M., et al. (2012). Pharmacological characterization of MK-6096-a dual orexin receptor antagonist for insomnia. Neuropharmacology 62, 978-987. doi: 10.1016/j.neuropharm.2011.10.003
45. Winrow, C. J., and Renger, J. J. (2014). Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br. J. Pharmacol. 171, 283-293. doi: 10.1111/bph.12261
46. Wismer, T. A. (2002). Accidental ingestion of alprazolam in 415 dogs. Vet. Hum. Toxicol. 44, 22-23.